Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +45.01%
#2 Mubarak Mubarak +39.83%
#3 Pons Pons +37.09%
#4 Starpower Starpower +34.73%
#5 Bitway Bitway +34.69%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +31.89%
#7 TENDIES TENDIES +27.14%
#8 SkyAI SkyAI +25.15%
#9 Ocean Protocol Ocean Protocol +21.53%
#10 Decred Decred +19.54%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
SynCore Biotechnology Co.,Ltd SynCore Biotechnology Co.,Ltd

SynCore Biotechnology Co.,Ltd

4192
Rang in Aktien #29314
SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the... SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the development and commercialization of biotechnology services, alongside offering expertise in food advisory and medicine inspection. The company's robust pipeline includes several promising drug candidates. Among its novel chemical entities (NCEs), SB01 is an injectable anti-cancer compound currently undergoing Phase II clinical trials for head and neck cancer. Another anti-cancer NCE, SB02, is in preclinical development, targeting stomach cancer. Beyond novel compounds, SynCore also markets established pharmaceutical solutions. This includes SB03-Veregen, an ointment prescribed for external genital and perianal warts. Its portfolio further extends to SB04, a conventional medication for age-related macular degeneration, presently in Phase II clinical studies. Additionally, SynCore is advancing SB05-EndoTAG, an established drug undergoing Phase III clinical trials for the treatment of both pancreatic cancer and triple-negative breast cancer. In a related venture, the company distributes epiCam brand cameras, which are designed for recording the progression of ophthalmic diseases. SynCore maintains strategic collaborations with notable entities such as Medigene AG, MacuCLEAR Inc., Sinphar Pharmaceutical Co., Ltd., and The National Health Research Institutes. Founded in 2008, SynCore Biotechnology Co.,Ltd is headquartered in Yilan City, Taiwan, and operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.
Aktienkurs
$0.62008105
Zuletzt synchronisiert: 2026-08-18
Marktkapitalisierung
$21.81M
Veränderung (1 Tag)
0.26%
Veränderung (1 Jahr)
-31.95%
Land
TW
Handel SynCore Biotechnology Co.,Ltd (4192)

Kategorie

Healthcare
Anzahl der ausstehenden Aktien von SynCore Biotechnology Co.,Ltd (4192)
Anzahl der ausstehenden Aktien zum August 2026: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von SynCore Biotechnology Co.,Ltd beträgt die aktuelle Anzahl der ausstehenden Aktien 0. Am Ende von August 2026 hatte das Unternehmen 0 ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von SynCore Biotechnology Co.,Ltd (4192) von 2026 bis 2026
Ausstehende Aktien am Ende jedes Jahres
Jahr Ausstehende Aktien ändert
Nicht genügend Daten für die angegebenen Daten.
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
Unternehmen Ausstehende Aktien Unterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH